Severe Side Effects of Mounjaro: Symptoms That Need Urgent Attention

What official safety data says about severe Mounjaro side effects

The clinical evidence base for tirzepatide is substantial. The SURMOUNT programme enrolled thousands of adults across its trials, and the safety signals that emerged are now embedded in the UK's regulatory framework. The NHS tirzepatide medicines page lists the serious effects clinicians watch for; the Mounjaro SmPC on the electronic medicines compendium adds the prescriber-level detail behind each warning.

The most consequential signal is acute pancreatitis. In January 2026, the MHRA published a Drug Safety Update across GLP-1 receptor agonist and dual-agonist medicines, confirming acute pancreatitis as an infrequent but potentially serious adverse effect. The defining symptom is severe, persistent pain in the upper abdomen that may radiate straight through to the back, sometimes accompanied by vomiting. If that matches what you're experiencing, stop the injection and get medical help the same day, don't try to manage it at home.

Gallbladder disease is a separate concern. Weight loss itself increases the risk of gallstones, and tirzepatide accelerates that process. Cholecystitis (gallbladder inflammation) and cholelithiasis (stones) both appear in post-marketing data. Sharp pain under the right ribs, especially after eating fatty food, combined with fever or yellowing skin, points toward the biliary tract rather than ordinary nausea.

Heart rate increase has also been observed in trials. A persistently elevated resting pulse, particularly one accompanied by dizziness or palpitations, is worth reporting to your prescriber rather than attributing it to general adjustment. For most people it is transient and mild, but it should not be silently ignored for weeks.

When severe Mounjaro side effects tip from manageable to urgent

There's a practical gradient here that's worth being honest about. Nausea after a dose increase is expected. Spending a morning feeling queasy is not an emergency. What changes the calculation is severity, persistence, and what the symptoms prevent you from doing.

Call 111 or go to A&E if you experience any of the following: severe abdominal pain (especially spreading to the back); signs of dehydration (no urine output for many hours, extreme dizziness on standing, confusion) after prolonged vomiting or diarrhoea that has made it impossible to keep fluids down; a swollen face, tongue or throat, or difficulty breathing, which may indicate a serious allergic reaction; yellowing of the eyes or skin; or sudden, marked changes in vision.

If you're reading this because you're already mid-symptom and worried, that instinct is probably right. A phone call to 111 takes a few minutes and a clinician will advise you. The severe diarrhoea guidance for Mounjaro covers the dehydration risk in more detail, and our page on severe constipation on Mounjaro addresses the opposite end of that spectrum. Both are manageable with the right support; both can escalate without it.

On the subject of mood: tirzepatide's SmPC includes a signal for low mood and, in rare cases, suicidal ideation. If you or someone close to you notices significant changes in mood or behaviour after starting treatment, contact your prescriber or GP promptly. It's an uncomfortable fact to name plainly, but it's in the guidance for a reason.

Serious severe side effects and the conditions that raise the risk

Not every person starting Mounjaro carries the same risk profile for severe reactions. The SmPC lists contraindications and precautions that prescribers weigh before approving treatment. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules tirzepatide out entirely under current UK licensing. A history of pancreatitis (even resolved) is a discussion point requiring careful prescriber judgement rather than an automatic approval.

People with pre-existing gallbladder disease, significant renal impairment, or a history of severe GI conditions should have those factors explicitly reviewed at consultation. This is exactly why the Mounjaro treatment overview frames clinical assessment as the starting point rather than a formality. The questions a prescriber asks aren't box-ticking; they're the mechanism by which the risk calculus actually gets personalised to you.

If you're already on Mounjaro and a new health condition emerges, tell your prescriber before the next dose. The clinical team at nume is available seven days a week for aftercare queries, that channel exists precisely for moments when something doesn't feel right between consultations.

Reporting and aftercare: your role in ongoing safety monitoring

The MHRA's Yellow Card scheme is not just a bureaucratic formality. Every report from a patient or carer adds to the post-marketing safety data that shapes prescribing guidance. If you suspect a Mounjaro side effect is more severe than anything described in the leaflet, or if you experience something unexpected, submitting a Yellow Card report at yellowcard.mhra.gov.uk is straightforward and takes under ten minutes.

Alongside that, keep a simple log: when you injected, what you ate, when the symptom started, and how long it lasted. That information is genuinely useful both for Yellow Card submissions and for prescriber conversations. If you want to understand what happens when loose stools become a more serious concern, our page on severe diarrhea on tirzepatide explains the warning signs and when to seek help. If you're thinking about your broader treatment journey, the weight-loss treatment options page sets the wider context, and our FAQ section covers practical questions that come up regularly. For anything that can't wait, reach out via the contact page and our clinical team will respond.

Our prescribers discuss suitability and the full side-effect profile as part of every consultation, including the serious end. If you're weighing whether Mounjaro is right for you, starting a free consultation is the right first step.